# Shanwan Biotech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/shanwan-biotech

- Industry: Biotechnology
- Headquarters: Suzhou, China
- Website: www.shanwanbiotech.com/
- Latest round: Series B (Apr 23, 2025)
- Investors on record: 1

## About

Founded in 2018 and based in Suzhou, China, Shanwan Biotech has concentrated on innovative long-acting and controlled-release drug formulations. Leveraging its location in the Yangtze River Delta, the company has built a foundation that combines in-house drug development with third-party formulation services, gradually expanding its presence in the biopharmaceutical sector. Shanwan Biotech develops and manufactures advanced sustained-release injectable formulations, with in-situ gel technology as its core platform. In addition to its proprietary drug pipeline, the company also provides contract development and manufacturing (CDMO) services, supporting other pharmaceutical firms with formulation innovation, process development, and production. The company generates revenue from the development, manufacturing, and sales of its pharmaceutical products, as well as from CDMO services offered to external partners.
In April 2025, Shanwan Biotech closed Series B funding from new investor Jiangsu Jinqiao Private Equity Fund Management.

## Funding rounds

- Series B, Apr 23, 2025 — Jiangsu Jinqiao Private Equity Fund Management

## Investors

- Jiangsu Jinqiao Private Equity Fund Management (https://capitalatlas.ai/funds/jiangsu-jinqiao-private-equity-fund-management) — Series B